WPD Pharmaceuticals (TSE:WBIO)
:WBIO
Top Page
No summary available
WPD Pharmaceuticals (WBIO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$324.76K
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,639,485
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio15.70
Price to Book (P/B)-230.88
Price to Sales (P/S)0.00
P/FCF Ratio-625.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
WPD Pharmaceuticals Business Overview & Revenue Model
Company Description
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the p...
How the Company Makes Money
WPD Pharmaceuticals makes money through the development and commercialization of its drug candidates. Revenue is primarily generated from licensing agreements, milestone payments, and royalties from strategic partnerships with larger pharmaceutica...
WPD Pharmaceuticals Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Mar 2024 | Dec 2023 | Dec 2021 | Mar 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -24.44K | -290.22K | -391.77K | ― |
| EBITDA | 63.10K | -40.43K | 4.05M | -5.24M | -7.11M | -11.45M |
| Net Income | -6.71K | -80.08K | 3.86M | -5.62M | -7.52M | -12.78M |
Balance Sheet | ||||||
| Total Assets | 292.54K | 346.41K | 75.85K | 1.86M | 2.68M | 4.07M |
| Cash, Cash Equivalents and Short-Term Investments | 9.34K | 85.86K | 23.79K | 1.71M | 1.24M | 2.95M |
| Total Debt | 390.88K | 303.90K | 0.00 | 1.04M | 115.38K | 254.51K |
| Total Liabilities | 914.82K | 902.37K | 554.64K | 5.92M | 1.58M | 864.48K |
| Stockholders Equity | -622.29K | -555.96K | -478.79K | -4.06M | 1.11M | 3.21M |
Cash Flow | ||||||
| Free Cash Flow | -171.99K | -205.10K | -3.47M | -1.56M | -2.03M | -235.52K |
| Operating Cash Flow | -171.99K | -205.10K | -3.43M | -1.49M | -1.38M | -170.40K |
| Investing Cash Flow | 7.37K | 0.00 | -239.05K | -70.98K | -645.46K | 2.81M |
| Financing Cash Flow | 30.50K | 267.17K | 1.23M | 992.22K | 1.02M | 380.92K |
WPD Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
TSE:WBIO
WPD Pharmaceuticals
0.07
0.00
0.00%
TSE:ENBI
Entheon Biomedical
0.10
-0.03
-23.08%
TSE:MYND
MYND Life Sciences
0.07
0.04
133.33%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.03
-75.00%
TSE:MBIO
Mindbio Therapeutics Corp.
1.15
-2.85
-71.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―